share_log

Novavax | DEFA14A: Others

Novavax | DEFA14A: Others

諾瓦瓦克斯醫藥 | DEFA14A：其他
美股sec公告 ·  04/29 20:03
牛牛AI助理已提取核心訊息
Novavax, Inc., a biotechnology company known for its vaccine development, has filed a definitive proxy statement with the United States Securities and Exchange Commission (SEC). The filing, made under Schedule 14A, is a requirement for companies that are soliciting shareholder votes. Novavax has confirmed that the proxy statement is definitive, indicating that it contains all the necessary information for shareholders to make informed decisions regarding the matters to be voted on. The company has also noted that no filing fee is required for this submission.
Novavax, Inc., a biotechnology company known for its vaccine development, has filed a definitive proxy statement with the United States Securities and Exchange Commission (SEC). The filing, made under Schedule 14A, is a requirement for companies that are soliciting shareholder votes. Novavax has confirmed that the proxy statement is definitive, indicating that it contains all the necessary information for shareholders to make informed decisions regarding the matters to be voted on. The company has also noted that no filing fee is required for this submission.
以疫苗開發聞名的生物技術公司Novavax, Inc. 已向美國證券交易委員會（SEC）提交了最終委託書。該文件是根據附表14A提交的，是向股東征集選票的公司的要求。Novavax已確認委託書是最終的，表明該委託書包含所有必要的信息，使股東可以就有待表決的事項做出明智的決定。該公司還指出，此次提交不需要任何申請費。
以疫苗開發聞名的生物技術公司Novavax, Inc. 已向美國證券交易委員會（SEC）提交了最終委託書。該文件是根據附表14A提交的，是向股東征集選票的公司的要求。Novavax已確認委託書是最終的，表明該委託書包含所有必要的信息，使股東可以就有待表決的事項做出明智的決定。該公司還指出，此次提交不需要任何申請費。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。